Highlight
- Advanced fibrosis (≥F3) affects 35% of biopsy-confirmed MASLD patients globally.
- Type 2 diabetes prevalence escalates with fibrosis severity, reaching 70% at cirrhosis stage (F4).
- Older age, type 2 diabetes, and obesity independently predict advanced fibrosis, mortality, and clinical events.
- Noninvasive tests (NITs) for fibrosis predict mortality and liver-related outcomes comparably to histologic assessment.
Study Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), represents a leading cause of chronic liver disease worldwide. The progression of MASLD to advanced fibrosis and cirrhosis critically influences morbidity and mortality, primarily through liver-related complications and associated metabolic comorbidities such as type 2 diabetes (T2D). Despite its global prevalence, predictors of fibrosis severity and clinical outcomes vary across diverse populations and require comprehensive characterization. Moreover, noninvasive tests (NITs) to identify advanced fibrosis have the potential to augment risk stratification and guide clinical management without the risks associated with liver biopsy. This large-scale Global-MASLD (G-MASLD) study was undertaken to elucidate clinical determinants of fibrosis severity in MASLD and to evaluate the prognostic value of histologic and noninvasive fibrosis markers for adverse clinical events and mortality worldwide.
Study Design
The Global-MASLD study enrolled 17,792 adult patients with biopsy-confirmed MASLD across multiple international centers, representing diverse ethnic and geographic backgrounds. Clinical data including demographics, metabolic comorbidities, and laboratory values were collected alongside liver histology and noninvasive test (NIT) measurements for fibrosis assessment. Liver fibrosis stages were categorized using standard histologic scoring, with advanced fibrosis defined as stage 3 or 4 (F3-F4). Patients were prospectively followed for a mean duration of 6.6 years to record mortality and liver-related clinical events such as hepatic decompensation and hepatocellular carcinoma. Multivariable analyses were performed to identify independent predictors of advanced fibrosis, mortality, and clinical events, adjusting for potential confounders. The prognostic performance of NITs was compared to histologic fibrosis staging in predicting outcomes.
Key Findings
Prevalence and Predictors of Advanced Fibrosis
Advanced fibrosis (F3-F4) was present in 35% of the cohort, highlighting a substantial burden of severe liver disease among MASLD patients globally. The prevalence of T2D demonstrated a clear, stepwise increase with fibrosis stage, rising from 28% in patients without fibrosis (F0) to 70% in those with cirrhosis (F4), with a statistically significant trend (p < 0.0001). Independent predictors of advanced fibrosis identified in multivariable logistic regression included older age, presence of T2D, and obesity. Notably, the association between obesity and advanced fibrosis varied regionally, suggesting environmental or genetic modifiers impact risk.
Clinical Outcomes and Mortality
Among patients with longitudinal follow-up, 6.5% died and 10.1% experienced clinically significant hepatic events such as liver decompensation or hepatocellular carcinoma. Older age, male sex, T2D, and obesity independently predicted both mortality and adverse clinical events, underscoring the interplay of metabolic dysfunction and demographic factors in MASLD progression. The severity of fibrosis, whether assessed histologically or by noninvasive fibrosis tests (NITs), was strongly associated with increased risk of death and liver-related complications, with adjusted hazard ratios exceeding 1.0 (p < 0.001). These data confirm that fibrosis stage remains the most critical prognostic marker in MASLD.
Prognostic Value of Noninvasive Tests
Noninvasive fibrosis markers, reflecting a combination of serum biomarkers and imaging modalities, effectively predicted mortality and liver-related outcomes in this large international cohort. Five-year mortality was low overall at 2.1% but increased markedly to 8.3% in patients with cirrhosis. Patients with high-risk NIT scores exhibited mortality rates exceeding 10%, supporting the clinical utility of these tests in identifying patients at elevated risk who might benefit from intensified monitoring or therapeutic intervention.
Expert Commentary
This extensive multinational study robustly validates the clinical importance of advanced fibrosis in MASLD as a key determinant of mortality and adverse liver events. The strong correlation between type 2 diabetes and fibrosis severity highlights the need for integrated management of metabolic comorbidities to potentially modify disease course. While liver biopsy remains the gold standard for staging fibrosis, the demonstration of equivalent prognostic capability of NITs offers a pragmatic pathway to risk stratification in routine practice, particularly important in resource-limited or high-volume clinical settings.
Limitations of the study include its observational design and potential referral bias inherent to biopsy-based cohorts. Regional variability in obesity’s impact suggests additional research into genetic and lifestyle factors is warranted. Future guidelines might incorporate these findings by emphasizing broader use of validated NITs combined with metabolic risk profiling to optimize patient outcomes globally.
Conclusion
The Global-MASLD study provides pivotal insights into the predictors of fibrosis, clinical events, and mortality in MASLD. Advanced fibrosis, strongly associated with type 2 diabetes, is prevalent among MASLD patients worldwide and independently predicts poor outcomes. Noninvasive fibrosis tests demonstrate substantial prognostic value, presenting an opportunity for enhanced, noninvasive risk assessment in clinical practice. These findings underscore the critical need for early identification and management of high-risk MASLD patients, integrating metabolic control with close fibrosis surveillance to mitigate progression and improve survival.
Funding and ClinicalTrials.gov
No specific funding disclosures or clinical trial registrations were provided in the source publication.
References
Younossi ZM, de Avila L, Petta S, et al. Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study. Hepatology. 2025 Nov 13;84(1):204-215. PMID: 41231627.
Further relevant literature for context:
- European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis.
- Kanwal F, Kramer JR, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828-1837.e2.
- Calzadilla-Bertot L, et al. Histological course of nonalcoholic fatty liver disease: Natural history and risk factors. Clin Liver Dis. 2020;24(1):1-14.
